Live Breaking News & Updates on Aurinia Renal Response

Stay updated with breaking news from Aurinia renal response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis . | May 3, 2023 ....

United States , United Kingdom , Great Britain , Peter Greenleaf , Healthcare Products Regulatory Agency , Aurinia Pharmaceuticals Inc , National Institute For Health , Aurinia Pharmaceuticals , National Institute , Care Excellence , Chief Executive Officer , European Commission Approved , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Renal Response , Active Lupus With Voclosporin , Renal Assessments , Aurinia Renal Response , Lupus With Voclosporin , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Ephritis Auph Ca05156v1022 ,

Aurinia Pharmaceuticals Inc.: Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option ....

United States , United Kingdom , Great Britain , Peter Greenleaf , Aurinia Pharmaceuticals , National Institute For Health , Aurinia Pharmaceuticals Inc , Healthcare Products Regulatory Agency , National Institute , Care Excellence , Chief Executive Officer , European Commission Approved , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Renal Response , Active Lupus With Voclosporin , Renal Assessments , Aurinia Renal Response , Lupus With Voclosporin ,

Otsuka announces MHRA authorisation of Lupkynis® (voclosporin) as first oral calcineurin-inhibitor ▼ (CNI) for active lupus nephritis

Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus . ....

United Kingdom , Northern Ireland , City Of , Great Britain , Otsuka Europe , Ryan Gynne , European Commission , Drug Administration , Otsuka Pharmaceutical Company Ltd , Peuropean League Against Rheumatism , European Union , Otsuka Pharmaceutical Europe Ltd , Otsuka Pharmaceutical Co Ltd , European Renal Association , Otsuka Holdings Co Ltd , Otsuka Pharmaceuticals United Kingdom Ltd , Healthcare Products Regulatory Agency , Otsuka Pharmaceuticals United Kingdom , Managing Director , Pharmaceutical Europe , Otsuka Pharmaceutical Company , Renal Response , Active Lupus With Voclosporin , Renal Assessments , Aurinia Renal Response , Lupus With Voclosporin ,